Shots:

• The FDA authorized EUA for bamlanivimab (700 mg) and etesevimab (1400 mg) for the treatment of mild to mod. COVID-19 patients aged ≥12yrs. who are at high risk for progressing to severe COVID-19 and/or hospitalization
• The EUA is based on P-III BLAZE-1 trial in ≥1-000 COVID-19 patients showed 70% reduction in hospitalizations. Lilly plans to manufacture 250-000+ doses in Q1’ 21 and up to 1M doses by mid-2021
• The FDA authorizes new protocols for infusion of bamlanivimab as monothx. and bamlanivimab and etesevimab together in as few as 16 and 21 min respectively

 ­ Ref: Businesswire | Image: Eli Lilly